Table 4 Comparison of characteristics between patients with BMI ≥ 24 and BMI < 24
|  | BMI ≥ 24 (n = 125) | BMI < 24 (n = 103) | P Value |
|---|---|---|---|
Age (years) | 53.0 (40.5–62.0) | 50.0 (36.0–63.0) | 0.194 |
Sex, female | 49 (39.2%) | 59 (57.3%) | 0.007 |
Age of diagnosis (years) | 41.0 (20.0-50.5) | 37.0 (23.0–51.0) | 0.838 |
Duration of asthma | 8.0 (4.0–20.0) | 6.0 (3.0–15.0) | 0.036 |
Pre-bronchodilator FEV1% pred (n = 219) | 66.0 ± 22.5 | 72.3 ± 25.4 | 0.055 |
Pre-bronchodilator FEV1/FVC (%) (n = 221) | 64.1 ± 12.9 | 65.8 ± 16.3 | 0.408 |
Post-bronchodilator FEV1% pred (n = 184) | 72.1 ± 22.3 | 80.7 ± 22.9 | 0.011 |
Post-bronchodilator FEV1/FVC (%) (n = 189) | 68.2 (61.5–78.3) | 71.8 (61.8–83.4) | 0.105 |
FENO, ppb (n = 161) | 37.5 (23.8–65.8) | 48.0 (26.0–95.0) | 0.169 |
Blood neutrophil (%) (n = 159) | 57.3 (50.8–62.9) | 57.1(50.7–66.1) | 0.799 |
Blood neutrophil (/ul) (n = 157) | 4100.0(3300.0-5500.0) | 3900.0 (3300.0-5200.0) | 0.630 |
Blood eosinophil (%) (n = 172) | 3.9 (2.1–8.2) | 3.4 (1.5–7.6) | 0.420 |
Blood eosinophil (/ul) (n = 168) | 235.0 (140.0-572.5) | 235.0 (110.0-530.5) | 0.514 |
Total IgE, IU/ml (n = 186) | 227.0 (96.6-564.5) | 272.0 (86.6-491.5) | 0.986 |
ACT score (n = 198) | 20.0 (17.0–21.0) | 21.0 (19.0–23.0) | 0.007 |
AQLQ score (n = 130) | 4.4 (3.5–5.4) | 4.7 (3.4–5.8) | 0.521 |
GINA step 5 | 54 (43.2%) | 42 (40.8%) | 0.712 |
Number of exacerbations | 0 (0–2) | 0 (0–2) | 0.568 |
Corticosteroids treatment for at least 3 days | 47 (37.6%) | 37 (35.9%) | 0.794 |
Emergency department visit or hospitalization | 23 (18.4%) | 17 (16.5%) | 0.687 |
Number of comorbidities (n = 183) | Â | Â | 0.018 |
0 | 10 (10.2%) | 13 (15.3%) | Â |
1 | 30 (30.6%) | 39 (45.9%) | Â |
2 | 32 (32.7%) | 24 (28.2%) | Â |
≥ 3 | 26 (26.5%) | 9 (10.6%) |  |